Full history for every metric is available with a Kvantra account
Acasti Pharma Inc. (ACST.V)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 8 | 12 | 20 | 18 | 14 | 21 |
| Operating profit | $m | -73 | -80 | |||||
| Net profit | $m | -13 | -16 | -43 | -44 | -76 | -65 | -69 |
| EPS reported | $ | -0.99 | -17.93 | |||||
| Operating cashflow per share | $ | -0.31 | -0.31 | |||||
| Capex per share | $ | 0.08 | 0.08 | |||||
| FCF per share | $ | -0.38 | -0.38 | |||||
| Free cash flow | $m | -25 | -37 | |||||
| Net debt | $m | -112 | -108 | |||||
| Book value equity | $m | 103 | 95 | |||||
| Book value per share | $ | 1.56 | 86.11 | |||||
| Number of shares | m | 65.51 | 1.1 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.35 | 0.19 | |||||
| P/S LTM | x | 2.54 | 0.88 | |||||
| P/FCF LTM | x | -1.45 | -0.48 | |||||
| EV/EBITDA LTM | x | 1.10 | 1.16 | |||||
| EV/Sales LTM | x | -5.35 | -4.36 | |||||
| Earnings Yield LTM | % | -179.09% | -243.36% | |||||
| FCF Yield | % | -69.01% | -206.44% | |||||
| Quality | ||||||||
| ROE | % | -63.32% | -67.58% | |||||
| ROIC | % | -54.78% | -54.78% | |||||
| Operating margin | % | -513.40% | -513.40% | |||||
| Gross margin | % | -371.72% | -371.72% | |||||
| FCF/Sales | % | -175.55% | -175.55% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -22.76% | +99.21% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.62 | 1.62 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -310.34% | -592.77% | |||||
| Net debt/Equity | x | -1.10 | -1.13 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Acasti Pharma Inc. is a biopharmaceutical company dedicated to the research, development, and market introduction of pharmaceutical solutions for cardiovascular conditions. The firm is currently exploring strategic collaborations to further the clinical advancement of its compound, CaPre. Established in 2002, Acasti Pharma Inc. maintains its principal operations from its headquarters in Laval, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Acasti Pharma Inc. (ACST.V)
Acasti Pharma Inc. is a biopharmaceutical company dedicated to the research, development, and market introduction of pharmaceutical solutions for cardiovascular conditions. The firm is currently exploring strategic collaborations to further the clinical advancement of its compound, CaPre. Established in 2002, Acasti Pharma Inc. maintains its principal operations from its headquarters in Laval, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free